FCF Payout Ratio: 45.34%
Is the FCF payout ratio high or low?
The FCF payout ratio of 45.34% is 24% below its 5-year average of 59.70%, near the low end of its 5-year range (39.40%–105.22%).
10.69% below its 12-month average of 50.76%.
GSK FCF Payout Ratio
Rolling trailing-12-month FCF payout ratio sampled each quarter; raw quarterly payout is intentionally not charted.
GSK Average FCF Payout Ratio Chart
GSK Current vs Average FCF Payout Ratio Chart
GSK FCF Payout Ratio Metrics
FCF PAYOUT RATIO
45.34%
FCF PAYOUT RATIO AVG TTM
50.76%
FCF PAYOUT RATIO AVG 3Y
51.22%
FCF PAYOUT RATIO AVG 5Y
55.22%
FCF PAYOUT RATIO AVG 10Y
66.24%
FCF PAYOUT RATIO AVG 15Y
75.47%
FCF PAYOUT RATIO AVG 20Y
73.03%
CURRENT VS TTM AVG
-10.69%
CURRENT VS 3Y AVG
-11.48%
CURRENT VS 5Y AVG
-17.90%
CURRENT VS 10Y AVG
-31.56%
CURRENT VS 15Y AVG
-39.93%
CURRENT VS 20Y AVG
-37.92%
Payout Ratio Comparison
FCF Payout Ratio TTM
45.3%
Earnings Payout Ratio
24.3%
Dividend Yield
3.51%
FCF Yield
7.87%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $7.84B | $3.37B | 43.1% |
| 2024 | $4.47B | $3.06B | 68.4% |
| 2023 | $7.96B | $3.55B | 44.6% |
| 2022 | $8.16B | $5.16B | 63.2% |
| 2021 | $7.17B | $5.41B | 75.5% |
| 2020 | $8.87B | $5.43B | 61.2% |
| 2019 | $7.76B | $5.24B | 67.5% |
| 2018 | $8.44B | $5.00B | 59.3% |
| 2017 | $6.37B | $5.27B | 82.8% |
| 2016 | $5.11B | $5.98B | 117.0% |
| 2015 | $984.16M | $5.71B | 579.9% |
| 2014 | $5.33B | $5.99B | 112.2% |
| 2013 | $9.15B | $6.10B | 66.7% |
| 2012 | $4.64B | $6.20B | 133.6% |
| 2011 | $7.65B | $5.29B | 69.2% |
| 2010 | $8.05B | $5.00B | 62.1% |
| 2009 | $9.65B | $5.00B | 51.8% |
| 2008 | $7.62B | $4.37B | 57.4% |
| 2007 | $7.24B | $5.57B | 76.9% |
| 2006 | $4.64B | $5.09B | 109.7% |
| 2005 | $7.58B | $4.11B | 54.2% |
| 2004 | $8.64B | $4.74B | 54.9% |
| 2003 | $6.76B | $4.16B | 61.6% |
| 2002 | $2.95B | $3.75B | 127.0% |
| 2001 | $5.08B | $3.39B | 66.7% |
| 2000 | $1.12B | $0 | 0.0% |
| 1999 | ($140.49M) | $0 | N/A (Loss) |
| 1998 | ($108.12M) | $0 | N/A (Loss) |
| 1997 | $330.48M | $0 | 0.0% |
| 1996 | $767.24M | $0 | 0.0% |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
FCF Payout Ratio FAQ
- What is the FCF payout ratio for GSK plc (GSK)?
- The FCF payout ratio for GSK stock is 45.34%.
- Is GSK plc's FCF payout ratio high or low?
- The FCF payout ratio of 45.34% is 24% below its 5-year average of 59.70%, near the low end of its 5-year range (39.40%–105.22%).
- What is the TTM average FCF payout ratio for GSK plc (GSK)?
- The TTM average FCF payout ratio for GSK stock is 50.76%.
- What is the 3Y average FCF payout ratio for GSK plc (GSK)?
- The 3Y average FCF payout ratio for GSK stock is 51.22%.
- What is the 5Y average FCF payout ratio for GSK plc (GSK)?
- The 5Y average FCF payout ratio for GSK stock is 55.22%.
- What is the 10Y average FCF payout ratio for GSK plc (GSK)?
- The 10Y average FCF payout ratio for GSK stock is 66.24%.
- What is the 15Y average FCF payout ratio for GSK plc (GSK)?
- The 15Y average FCF payout ratio for GSK stock is 75.47%.
- What is the 20Y average FCF payout ratio for GSK plc (GSK)?
- The 20Y average FCF payout ratio for GSK stock is 73.03%.
GSK FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2026-03-31 | 45.34% |
| 2025-12-31 | 44.75% |
| 2025-09-30 | 46.53% |
| 2025-06-30 | 53.19% |
| 2025-03-31 | 64.02% |
| 2024-12-31 | 63.76% |
| 2024-09-30 | 45.07% |
| 2024-06-30 | 41.54% |
| 2024-03-31 | 39.40% |
| 2023-12-31 | 46.37% |
| 2023-09-30 | 73.42% |
| 2023-06-30 | 99.41% |
| 2023-03-31 | 105.22% |
| 2022-12-31 | 64.47% |
| 2022-09-30 | 47.74% |
| 2022-06-30 | 43.65% |
| 2022-03-31 | 49.18% |
| 2021-12-31 | 60.83% |
| 2021-09-30 | 62.91% |
| 2021-06-30 | 90.38% |
| 2021-03-31 | 66.59% |
| 2020-12-31 | 59.43% |
| 2020-09-30 | 67.11% |
| 2020-06-30 | 50.99% |
| 2020-03-31 | 64.14% |
| 2019-12-31 | 67.40% |
| 2019-09-30 | 59.68% |
| 2019-06-30 | 63.30% |
| 2019-03-31 | 61.26% |
| 2018-12-31 | 60.50% |
| 2018-09-30 | 73.98% |
| 2018-06-30 | 77.25% |
| 2018-03-31 | 86.82% |
| 2017-12-31 | 81.77% |
| 2017-09-30 | 82.71% |
| 2017-06-30 | 85.14% |
| 2017-03-31 | 99.17% |
| 2016-12-31 | 122.63% |
| 2016-09-30 | 178.01% |
| 2016-06-30 | 323.56% |
| 2016-03-31 | 733.55% |
| 2015-12-31 | 606.59% |
| 2015-09-30 | 262.05% |
| 2015-06-30 | 167.24% |
| 2015-03-31 | 135.38% |
| 2014-12-31 | 114.57% |
| 2014-09-30 | 109.32% |
| 2014-06-30 | 89.09% |
| 2014-03-31 | 71.92% |
| 2013-12-31 | 66.03% |
| 2013-09-30 | 69.30% |
| 2013-06-30 | 124.56% |
| 2013-03-31 | 127.59% |
| 2012-12-31 | 133.98% |
| 2012-09-30 | 122.51% |
| 2012-06-30 | 70.42% |
| 2012-03-31 | 69.64% |
| 2011-12-31 | 69.57% |
| 2011-09-30 | 79.07% |
| 2011-06-30 | 100.41% |
| 2011-03-31 | 80.51% |
| 2010-12-31 | 62.48% |
| 2010-09-30 | 54.98% |
| 2010-06-30 | 44.98% |
| 2010-03-31 | 47.55% |
| 2009-12-31 | 50.38% |
| 2009-09-30 | 52.33% |
| 2009-06-30 | 51.89% |
| 2009-03-31 | 61.51% |
| 2008-12-31 | 59.13% |
| 2008-09-30 | 61.97% |
| 2008-06-30 | 65.57% |
| 2008-03-31 | 60.95% |
| 2007-12-31 | 69.36% |
| 2007-09-30 | 65.69% |
| 2007-06-30 | 114.37% |
| 2007-03-31 | 120.37% |
| 2006-12-31 | 94.92% |
| 2006-09-30 | 90.26% |
| 2006-06-30 | 51.74% |
| 2006-03-31 | 46.12% |
| 2005-12-31 | 49.15% |
| 2005-09-30 | 58.22% |
| 2005-06-30 | 95.88% |
| 2005-03-31 | 59.07% |
| 2004-12-31 | 36.97% |
| 2004-09-30 | 66.40% |
| 2004-06-30 | 27.35% |
| 2004-03-31 | 42.80% |
| 2003-12-31 | 60.75% |
| 2003-09-30 | 36.05% |
| 2003-06-30 | 38.11% |
| 2003-03-31 | 39.15% |
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels